MedTrace Logo

Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer

NCT00920816 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 492

Last updated 2022-05-06

Study results available
· View outcomes & findings →

Summary

The study is designed to demonstrate that axitinib (AG-013736) is superior to sorafenib in delaying tumor progression in patients with metastatic renal cell cancer.

Conditions

  • Kidney Neoplasms

Interventions

DRUG

Axitinib (AG-013736)

axitinib will be given at a starting dose of 5 mg BID with continuous dosing

DRUG

Sorafenib

sorafenib will be given at a dose of 400 mg BID continuous dosing

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-25
Primary Completion
2012-07-27
Completion
2021-04-29

Countries

  • United States
  • Bosnia and Herzegovina
  • Bulgaria
  • Chile
  • China
  • India
  • Malaysia
  • Mexico
  • Philippines
  • Romania
  • Russia
  • South Africa
  • Taiwan
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00920816 on ClinicalTrials.gov